CHENGDU, China, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Inc., (Clover; Stock code: 2197.HK), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that the first participants have been dosed with Clover’s COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), as a homologous booster dose following primary vaccination of SCB-2019 (CpG 1018/Alum) in the ongoing global Phase 2/3 SPECTRA clinical trial. Clover reported final efficacy data for SCB-2019 (CpG 1018/Alum) in SPECTRA in September 2021 and the study is continuing to generate additional immunogenicity and safety data.
This double-blind, randomized, controlled study will evaluate the immunogenicity and safety of two formulations of SCB-2019 (full dose: 30 µg with CpG 1018/Alum and half dose: 15 µg with CpG 1018/Alum) as a homologous booster dose administered approximately 6 months following 2-dose primary vaccination with SCB-2019 (CpG 1018/Alum) in approximately 4,000 adult participants.
In addition, the evaluation of the immunogenicity and safety of SCB-2019 (CpG 1018/Alum) for primary vaccination in the adolescent (12-18 years) subgroup has been expanded to 1,200 adolescents. Initial data on both the homologous booster arm and adolescents are anticipated in the first half of 2022.